Acta Medica Okayama JUNE2008. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Ikuko Miyazaki Masato Asanuma

Size: px
Start display at page:

Download "Acta Medica Okayama JUNE2008. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Ikuko Miyazaki Masato Asanuma"

Transcription

1 Acta Medica Okayama Volume 62, Issue Article 1 JUNE2008 Dopaminergic neuron-specific oxidative stress caused by dopamine itself Ikuko Miyazaki Masato Asanuma Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, miyazaki@cc.okayama-u.ac.jp Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.

2 Dopaminergic neuron-specific oxidative stress caused by dopamine itself Ikuko Miyazaki and Masato Asanuma Abstract Oxidative stress, including the reactive oxygen or nitrogen species generated in the enzymatical oxidationor auto-oxidation of an excess amount of dopamine, is thought to play an important role in dopaminergic neurotoxicity. Dopamine and its metabolites containing 2 hydroxyl residues exert cytotoxicityin dopaminergic neuronal cells, primarily due to the generation of highly reactive dopamine and DOPA quinones. Dopamine and DOPA quinones may irreversibly alter protein function through the formation of 5-cysteinyl-catechols on the proteins. Furthermore, the quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases. Therefore, pathogenic effects of the dopamine quinone have recently focused on dopaminergicneuron-specific oxidative stress. In this article, we primarily review recent studies on the pathogenicity of quinone formation, in addition to several neuroprotective approaches against dopaminequinone-induced dysfunction of dopaminergic neurons. KEYWORDS: dopamine quinone, quinoprotein, methamphetamine, Parkinson?s disease, L-DOPA Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved PMID:

3 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine Dopaminergic Neuron-Specific Oxidative Stress Caused by Dopamine Itself * ʼ ʼ Produced by The Berkeley Electronic Press,

4 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art. 1 ʼ ʼ 2

5 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ,,,,, Produced by The Berkeley Electronic Press,

6 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art. 1 ʼ 4

7 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ ʼ ʼ Produced by The Berkeley Electronic Press,

8 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art. 1 ʼ 6

9 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ Produced by The Berkeley Electronic Press,

10 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art ʼ ʼ ʼ ʼ ʼ ʻ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ

11 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ Produced by The Berkeley Electronic Press,

12 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art ʼ

Acta Medica Okayama. Jichun Wang Hiroyuki Matsuoka Makoto Hirai Ling Mu Liandi Yang Enjie Luo

Acta Medica Okayama. Jichun Wang Hiroyuki Matsuoka Makoto Hirai Ling Mu Liandi Yang Enjie Luo Acta Medica Okayama Volume 64, Issue 1 2010 Article 7 FEBRUARY 2010 The First Case of a Class I Glucose-6-phosphate Dehydrogenase Deficiency, G6PD Santiago de Cuba (1339 GA), in a Chinese Population as

More information

Acta Medica Okayama. Initial Report of Hybrid Radical Prostatectomy for Prostate Cancer:Reduced Bleeding, Clear Vision, and Secure Surgical Margins

Acta Medica Okayama. Initial Report of Hybrid Radical Prostatectomy for Prostate Cancer:Reduced Bleeding, Clear Vision, and Secure Surgical Margins Acta Medica Okayama Volume 62, Issue 6 2008 Article 4 DECEMBER 2008 Initial Report of Hybrid Radical Prostatectomy for Prostate Cancer:Reduced Bleeding, Clear Vision, and Secure Surgical Margins Takashi

More information

Acta Medica Okayama. Differential, histochemical and immunohistochemical changes in rat hepatocytes after isoflurane or sevoflurane exposure.

Acta Medica Okayama. Differential, histochemical and immunohistochemical changes in rat hepatocytes after isoflurane or sevoflurane exposure. Acta Medica Okayama Volume 57, Issue 1 2003 Article 1 FEBRUARY 2003 Differential, histochemical and immunohistochemical changes in rat hepatocytes after isoflurane or sevoflurane exposure. Mayumi Honda

More information

Acta Medica Okayama APRIL 2001

Acta Medica Okayama APRIL 2001 Acta Medica Okayama Volume 55, Issue 2 2001 Article 7 APRIL 2001 Comparison of chromosome aberrations in peripheral blood lymphocytes from people occupationally exposed to ionizing and radiofrequency radiation.

More information

Acta Medica Okayama. A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death.

Acta Medica Okayama. A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death. Acta Medica Okayama Volume 59, Issue 6 2005 Article 4 DECEMBER 2005 A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death. Jian Huang Lijun

More information

Acta Medica Okayama. Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma APRIL Volume 51, Issue Article 6

Acta Medica Okayama. Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma APRIL Volume 51, Issue Article 6 Acta Medica Okayama Volume 51, Issue 2 1997 Article 6 APRIL 1997 Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma Eiichi Makihata, Okayama University Masahiro Kuroda,

More information

Acta Medica Okayama AUGUST A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections.

Acta Medica Okayama AUGUST A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Medica Okayama Volume 58, Issue 4 2004 Article 1 AUGUST 2004 A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Keiji Iwatsuki Takenobu Yamamoto

More information

Acta Medica Okayama OCTOBER Mastectomy in Female-to-male Transsexuals. Yuzaburo Namba Toshiyuki Watanabe Yoshihiro Kimata

Acta Medica Okayama OCTOBER Mastectomy in Female-to-male Transsexuals. Yuzaburo Namba Toshiyuki Watanabe Yoshihiro Kimata Acta Medica Okayama Volume 63, Issue 5 2009 Article 4 OCTOBER 2009 Mastectomy in Female-to-male Transsexuals Yuzaburo Namba Toshiyuki Watanabe Yoshihiro Kimata Department of Plastic and Reconstructive

More information

Acta Medica Okayama. Differentiation of thyroid nodules using Tl-201 scintigraphy quantitative analysis and fine-needle aspiration biopsy.

Acta Medica Okayama. Differentiation of thyroid nodules using Tl-201 scintigraphy quantitative analysis and fine-needle aspiration biopsy. Acta Medica Okayama Volume 58, Issue 2 2004 Article 3 APRIL 2004 Differentiation of thyroid nodules using Tl-201 scintigraphy quantitative analysis and fine-needle aspiration biopsy. Yasuhiro Yamamoto,

More information

Acta Medica Okayama. Abscess Formation of the Round Ligament of the Liver: Report of a Case

Acta Medica Okayama. Abscess Formation of the Round Ligament of the Liver: Report of a Case Acta Medica Okayama Volume 62, Issue 6 2008 Article 8 DECEMBER 2008 Abscess Formation of the Round Ligament of the Liver: Report of a Case Kazunori Tsukuda Shiro Furutani Saki Nakahara Akihiro Tada Keitaro

More information

Acta Medica Okayama. Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. DECEMBER Volume 57, Issue Article 1

Acta Medica Okayama. Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. DECEMBER Volume 57, Issue Article 1 Acta Medica Okayama Volume 57, Issue 6 2003 Article 1 DECEMBER 2003 Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. Akira Okamoto Masahiro Yamamura Mitsuhiro Iwahashi Tetsushi

More information

Acta Medica Okayama. Metastatic carcinoma of the colon similar to Crohn s disease: a case report. AUGUST Volume 58, Issue Article 7

Acta Medica Okayama. Metastatic carcinoma of the colon similar to Crohn s disease: a case report. AUGUST Volume 58, Issue Article 7 Acta Medica Okayama Volume 58, Issue 4 2004 Article 7 AUGUST 2004 Metastatic carcinoma of the colon similar to Crohn s disease: a case report. Kohji Tanakaya Hitoshi Takeuchi Yoshimasa yasui Akira Takeda

More information

Acta Medica Okayama. Sneddon s syndrome: clinical and laboratory analysis of 10 cases. APRIL Volume 58, Issue Article 1

Acta Medica Okayama. Sneddon s syndrome: clinical and laboratory analysis of 10 cases. APRIL Volume 58, Issue Article 1 Acta Medica Okayama Volume 58, Issue 2 2004 Article 1 APRIL 2004 Sneddon s syndrome: clinical and laboratory analysis of 10 cases. Ertugrul Bolayir Abdulkerim Yilmaz Nesim Kugu Haydar Erdogan Melih Akyol

More information

Abstracts and affiliations

Abstracts and affiliations Dopamine Discovery Day August 30, 2012 Rikshospitalet Store auditorium, Oslo, Norway Organized by Linda H. Bergersen & Vidar Gundersen Institute of Basic Medical Sciences & Centre for Molecular Biology

More information

The Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone

The Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.

More information

3 O Methyldopa inhibits astrocyte mediated dopaminergic neuroprotective effects of l DOPA

3 O Methyldopa inhibits astrocyte mediated dopaminergic neuroprotective effects of l DOPA DOI 10.1186/s12868-016-0289-0 BMC Neuroscience RESEARCH ARTICLE Open Access 3 O Methyldopa inhibits astrocyte mediated dopaminergic neuroprotective effects of l DOPA Masato Asanuma 1,2* and Ikuko Miyazaki

More information

Acta Medica Okayama APRIL 1963

Acta Medica Okayama APRIL 1963 Acta Medica Okayama Volume 17, Issue 2 1963 Article 4 APRIL 1963 Influence of local pressure on athetoid, electro-myogram of spastic paraplegia in water, and influence of oxygen inhalation on the tone

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information

Acta Medica Okayama. Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report.

Acta Medica Okayama. Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report. Acta Medica Okayama Volume 58, Issue 2 2004 Article 7 APRIL 2004 Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report. Nilgun Erten Bulent Saka M Akif

More information

E. Haritov, E. Angeleska and N. Boyadjieva Department of pharmacology and toxicology, Medical Faculty, Medical University So a

E. Haritov, E. Angeleska and N. Boyadjieva Department of pharmacology and toxicology, Medical Faculty, Medical University So a :.,..,, KETOGENIC DIET AND EPILEPSY: THE ROLE OF KETONE BODIES IN THE INFLUENCE N NEURONAL EXCITABILITY E. Haritov, E. Angeleska and N. Boyadjieva Department of pharmacology and toxicology, Medical Faculty,

More information

Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson s disease

Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson s disease Baranyi et al. Molecular Neurodegeneration (2016) 11:6 DOI 10.1186/s13024-015-0067-y RESEARCH ARTICLE Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson

More information

Integrative approaches to Parkinson s Disease

Integrative approaches to Parkinson s Disease Integrative approaches to Parkinson s Disease Brian Harris Kopell, M.D. C0-Director, Center for Neuromodulation Associate Professor Departments of Neurosurgery, Neurology, Psychiatry and Neuroscience An

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Summary and Conclusion

Summary and Conclusion Parkinson s disease is a progressive disorder of the nervous system primarily affecting the motor system of the body and is also known as Shaking palsy (Bendick, 2002). Parkinson's disease is the second

More information

Acta Medica Okayama AUGUST Normal chemotactic activity of granulocytes obtained by filtration leucapheresis

Acta Medica Okayama AUGUST Normal chemotactic activity of granulocytes obtained by filtration leucapheresis Acta Medica Okayama Volume 31, Issue 4 1977 Article 7 AUGUST 1977 Normal chemotactic activity of granulocytes obtained by filtration leucapheresis Hironobu Toki Koichi Kitajima Isao Takahashi Masaaki Tokioka

More information

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,

More information

Acta Medica Okayama JUNE 2009

Acta Medica Okayama JUNE 2009 Acta Medica Okayama Volume 63, Issue 3 29 Article 1 JUNE 29 Radiographic Prediction of the Results of Long-term Treatment with the Pavlik Harness for Developmental Dislocation of the Hip Takao Ohmori Hirosuke

More information

Acta Medica Okayama. Masana Ogata FEBRUARY Volume 16, Issue Article 2. Okayama University,

Acta Medica Okayama. Masana Ogata FEBRUARY Volume 16, Issue Article 2. Okayama University, Acta Medica Okayama Volume 16, Issue 1 1962 Article 2 FEBRUARY 1962 Studies on the protein synthesis in poisoning. III. Labeling of ph-5 enzyme with C14-glycine and the inhibition by para chloromercuribenzoate

More information

Acta Medica Okayama. Studies on diagnosis of leukemia by tissue culture. Kiyoshi Hiraki APRIL Volume 12, Issue Article 8

Acta Medica Okayama. Studies on diagnosis of leukemia by tissue culture. Kiyoshi Hiraki APRIL Volume 12, Issue Article 8 Acta Medica Okayama Volume 12, Issue 1 1958 Article 8 APRIL 1958 Studies on diagnosis of leukemia by tissue culture Kiyoshi Hiraki Okayama University, Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL.

More information

Acta Medica Okayama JULY Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine

Acta Medica Okayama JULY Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine Acta Medica Okayama Volume 32, Issue 3 1978 Article 1 JULY 1978 Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine Akiharu Watanabe Norio Hobara Hideo Nagashima Okayama University,

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

The Shaking Palsy of 1817

The Shaking Palsy of 1817 The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms

More information

metabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine

metabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine 6XPPDU\ Parkinson s disease is a serious neurological disorder of the central nervous system that usually becomes apparent after the age of 55. It concerns the increased deterioration of neurons responsible

More information

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:

More information

Oxidative Mechanisms and Tardive Dyskinesia

Oxidative Mechanisms and Tardive Dyskinesia REVIEW ARTICLE CNS Drugs 2003; 17 (1): 47-62 1172-7047/03/0001-0047/$30.00/0 Adis International Limited. All rights reserved. Oxidative Mechanisms and Tardive Dyskinesia James B. Lohr, Ronald Kuczenski

More information

PHRM20001: Pharmacology - How Drugs Work!

PHRM20001: Pharmacology - How Drugs Work! PHRM20001: Pharmacology - How Drugs Work Drug: a chemical that affects physiological function in a specific way. Endogenous substances: hormones, neurotransmitters, antibodies, genes. Exogenous substances:

More information

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the

More information

Acta Medica Okayama. Electron microscopic demonstration of a new virus isolated from a patient with SMON. Zensuke Ota DECEMBER 1970

Acta Medica Okayama. Electron microscopic demonstration of a new virus isolated from a patient with SMON. Zensuke Ota DECEMBER 1970 Acta Medica Okayama Volume 24, Issue 6 1970 Article 3 DECEMBER 1970 Electron microscopic demonstration of a new virus isolated from a patient with SMON Zensuke Ota Okayama University, Copyright c 1999

More information

01/11/2012. Neurological disorders and nutrition. Nutritional and related assessments. Non-nutritional causes: nutritional implications

01/11/2012. Neurological disorders and nutrition. Nutritional and related assessments. Non-nutritional causes: nutritional implications Neurological disorders and nutrition General considerations, e.g., dysphagia Main topics and optional Canadian websites: STROKES www.heartandstroke.ca EPILEPSY www.epilepsy.ca PARKINSON S www.parkinson.ca

More information

Ph D THESIS ABSTRACT

Ph D THESIS ABSTRACT ALEXANDRU IOAN CUZA UNIVERSITY IAŞI FACULTY OF BIOLOGY THE STUDY OF CHANGES FOR SEVERAL BIOCHEMICAL PARAMETERS OF OXIDATIVE STRESS IN ANIMAL MODELS FOR NEUROPSYCHIATRIC DISORDERS Ph D THESIS ABSTRACT Scientific

More information

Superoxide dismutase activity and zinc and copper concentrations in Parkinson s disease

Superoxide dismutase activity and zinc and copper concentrations in Parkinson s disease Pathophysiology 7 (2000) 63 67 www.elsevier.com/locate/pathophys Superoxide dismutase activity and zinc and copper concentrations in Parkinson s disease Pelin Aribal Kocatürk a, *, M. Cenk Akbostanci b,

More information

Acta Medica Okayama OCTOBER Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus

Acta Medica Okayama OCTOBER Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus Acta Medica Okayama Volume 31, Issue 5 1977 Article 4 OCTOBER 1977 Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus Koichi Kawanishi Hidenori Ueda Masayuki Nagase Tadashi

More information

Acta Medica Okayama. Takashi Seno FEBRUARY Volume 22, Issue Article 4. Okayama University,

Acta Medica Okayama. Takashi Seno FEBRUARY Volume 22, Issue Article 4. Okayama University, Acta Medica Okayama Volume 22, Issue 1 1968 Article 4 FEBRUARY 1968 Protein concentration of synovial fluid in chronic rheumatoid arthritis. Estimation of protein in the synovial fluid of chronic rheumatoid

More information

Dopamine metabolism. JOURNAL OF NEUROCHEMISTRY doi: /jnc.12686

Dopamine metabolism. JOURNAL OF NEUROCHEMISTRY doi: /jnc.12686 JOURNAL OF NEUROCHEMISTRY 2014 129 898 915 doi: 10.1111/jnc.12686, *Faculty of Medicine, Molecular and Clinical Pharmacology, ICBM, University of Chile, Santiago, Chile Departamento de Ciencias Basicas,

More information

Impact of vitamins & nutrients on neurological function. B-vitamins and aging. Nafisa Jadavji, PhD

Impact of vitamins & nutrients on neurological function. B-vitamins and aging. Nafisa Jadavji, PhD Impact of vitamins & nutrients on neurological function B-vitamins and aging Nafisa Jadavji, PhD nafisa.jadavji@carleton.ca Lecture Outline Answer to questions from last class Homocysteine Vitamin B9:

More information

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin

Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin Pettit et al. Lipids in Health and Disease 213, 12:16 RESEARCH Open Access Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin Lauren K Pettit 1, Christopher

More information

Acta Medica Okayama APRIL 1974

Acta Medica Okayama APRIL 1974 Acta Medica Okayama Volume 28, Issue 2 1974 Article 4 APRIL 1974 Carcinogenesis in tissue culture. 22. Malignant transformation of cloned rat liver cells treated in culture with 4-dimethylaminoazobenzene

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

Follow this and additional works at: Part of the Medicinal Chemistry and Pharmaceutics Commons

Follow this and additional works at:  Part of the Medicinal Chemistry and Pharmaceutics Commons Wayne State University Wayne State University Dissertations 1-1-2013 Design, Synthesis, Biological Evaluation And Molecular Modeling Studies Of Novel Multifunctional Neuroprotective Drugs For The Treatment

More information

Modeling Parkinson s disease: systems to test gene-environment interactions

Modeling Parkinson s disease: systems to test gene-environment interactions Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)

More information

Targeting the Progression of Parkinson s Disease

Targeting the Progression of Parkinson s Disease Targeting the Progression of Parkinson s Disease Current Neuropharmacology, 2009, 7, 9-36 9 J.L. George 1, S. Mok 1, D. Moses 2, S. Wilkins 1, A.I. Bush 1, R.A. Cherny 1 and D.I. Finkelstein 1,* 1 The

More information

NEUROPLASTICITY IN THE NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT THE PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM

NEUROPLASTICITY IN THE NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT THE PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM NEUROPLASTICITY IN E NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT E PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM Michael V. Ugrumov Institute of Developmental Biology RAS, Moscow, Russia

More information

Evaluations & CE. With Support From. Featured Speaker 1/20/2016. Conflict of Interest & Disclosure Statements

Evaluations & CE. With Support From. Featured Speaker 1/20/2016. Conflict of Interest & Disclosure Statements With Support From University at Albany School of Public Health New York State Department of Health New York State Association of County Health Officials (NYSACHO) Parkinson s Disease: The Importance of

More information

Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease

Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease Oxidative Stress laboratory Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease By Dr. Soliman Khatib Senior lecturer,

More information

P. Riederer, D. B. CaIne, R. Horowski, Y. Mizuno, W. Poewe, M. B. H. Youdim (eds.) Advances in Research on N eurodegeneration.

P. Riederer, D. B. CaIne, R. Horowski, Y. Mizuno, W. Poewe, M. B. H. Youdim (eds.) Advances in Research on N eurodegeneration. P. Riederer, D. B. CaIne, R. Horowski, Y. Mizuno, W. Poewe, M. B. H. Youdim (eds.) Advances in Research on N eurodegeneration Volume 5 Springer WienN ewyork Prof. Dr. P. Riederer Department of Psychiatry,

More information

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical

More information

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there

More information

Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche

Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche LA NEUROSONOLOGIA NELLE PATOLOGIE DEGENERATIVE E VASCOLARI CEREBRALI San Benedetto del Tronto 6-8 novembre 2017 Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche Giuseppe De Michele

More information

Bee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS

Bee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS Bee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS MONA MOSTAFA FARID 1 Introduction 2 Bee venom have been widely used in Oriental medicine to relieve pain

More information

Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology

Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Marcel Leist In Vitro Toxicology and Biomedicine Doerenkamp-Zbinden Chair, University of Konstanz, Germany

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS

More information

Acta Medica Okayama OCTOBER 1958

Acta Medica Okayama OCTOBER 1958 Acta Medica Okayama Volume 12, Issue 3 1958 Article 4 OCTOBER 1958 A histochemical study of the red and white muscle fibers Part I. Activity of the succinoxydase system in muscle fibers Takuro Ogata Okayama

More information

CHAPTER 1 INTRODUCTION

CHAPTER 1 INTRODUCTION CAPTER 1 ITRDUCTI 1.1 GEERAL BACKGRUD In 1817, James Parkinson wrote a monograph Essay on the Shaking Palsy, in which he described six patients who had involuntary tremulous movements, whose muscles were

More information

Mechanistic Toxicology

Mechanistic Toxicology SECOND EDITION Mechanistic Toxicology The Molecular Basis of How Chemicals Disrupt Biological Targets URS A. BOELSTERLI CRC Press Tavlor & France Croup CRC Press is an imp^t o* :H Taylor H Francn C'r,,jpi

More information

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE MOLECULAR DOCKING OF QUERCETIN, HESPERIDIN AND L-DOPA WITH MITOCHONDRIAL PROTEINS RELATED TO PARKINSON S DISEASE SRIMATHI PRIYANGA. K 1, VIJAYALAKSHMI. K 2 1. Research scholar, Department of biochemistry,

More information

Welcome and Introductions

Welcome and Introductions Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1

More information

Conversionofaminoacidsto specializedproducts

Conversionofaminoacidsto specializedproducts Conversionofaminoacidsto specializedproducts α-nitrogen atom of amino acids is a primary source for many nitrogenous compounds: Heme Purines and pyrimidines Hormones Neurotransmitters Biologically active

More information

Acta Medica Okayama. Studies on the Etiology of Glaucoma Part 4. On the Effector Organs in Eyeball. Goro Akagi JUNE 1957

Acta Medica Okayama. Studies on the Etiology of Glaucoma Part 4. On the Effector Organs in Eyeball. Goro Akagi JUNE 1957 Acta Medica Okayama Volume 11, Issue 2 1957 Article 3 JUNE 1957 Studies on the Etiology of Glaucoma Part 4. On the Effector Organs in Eyeball Goro Akagi Okayama University, Copyright c 1999 OKAYAMA UNIVERSITY

More information

ANTIOXIDANT ACTIVITY OF β-carboline DERIVATIVES

ANTIOXIDANT ACTIVITY OF β-carboline DERIVATIVES Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 68 No. 2 pp. 185ñ189, 2011 ISSN 0001-6837 Polish Pharmaceutical Society DRUG BIOCHEMISTRY ANTIOXIDANT ACTIVITY OF β-carboline DERIVATIVES RENATA FRANCIK

More information

THE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT

THE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT Jundishapur Journal of Natural Pharmaceutical Products 7; (): 8- Jundishapur Journal of Natural Pharmaceutical Products THE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT

More information

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd. Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed

More information

Edaravone: A Review on Analytical Method and its Determination in Biological Matrix and Synthetic Mixture

Edaravone: A Review on Analytical Method and its Determination in Biological Matrix and Synthetic Mixture 80 Review Article Edaravone: A Review on Analytical Method and its Determination in Biological Matrix and Synthetic Mixture Patel Divya A. 1 *, Raj Hasumati 1, Patel Roshni 2 1 Department of Quality Assurance,

More information

HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA

HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA 95926 and Department of Physiology and Pharmacology,

More information

Neuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU

Neuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific

More information

This student paper was written as an assignment in the graduate course

This student paper was written as an assignment in the graduate course 77:222 Spring 2003 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2003) offered

More information

Reactive dopamine metabolites and neurotoxicity : the role of GAPDH and pesticide exposure in Parkinson's disease pathology

Reactive dopamine metabolites and neurotoxicity : the role of GAPDH and pesticide exposure in Parkinson's disease pathology University of Iowa Iowa Research Online Theses and Dissertations Spring 2016 Reactive dopamine metabolites and neurotoxicity : the role of GAPDH and pesticide exposure in Parkinson's disease pathology

More information

Acta Medica Okayama. Malignant fibrous histiocytoma with skeletal involvement. Hideo Takechi Kohji Taguchi OCTOBER 1978

Acta Medica Okayama. Malignant fibrous histiocytoma with skeletal involvement. Hideo Takechi Kohji Taguchi OCTOBER 1978 Acta Medica Okayama Volume 32, Issue 5 1978 Article 4 OCTOBER 1978 Malignant fibrous histiocytoma with skeletal involvement Hideo Takechi Kohji Taguchi Okayama University, Okayama University, Copyright

More information

This dissertation is available at Iowa Research Online:

This dissertation is available at Iowa Research Online: University of Iowa Iowa Research Online Theses and Dissertations 2012 Covalent modification and inhibition of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, an endogenously produced neurotoxin

More information

CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease

CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease Brain Diseases Symposium, Helsinki 14 Oct 2016 Pekka Simula, CEO, Herantis Pharma Plc 1 Disclaimer This presentation

More information

Neurodegenerative diseases

Neurodegenerative diseases Neurodegenerative diseases Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani Hiwa.saaed@univsul.edu.iq 2018-19 Neurodegenerative diseases of the CNS

More information

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a

More information

Biochimica et Biophysica Acta

Biochimica et Biophysica Acta Biochimica et Biophysica Acta 1822 (212) 1125 1136 Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis verexpression of VMAT-2

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION doi:10.1038/nature13418 Supplementary Results: USP30 opposes autophagic flux In HEK-293 cells, USP30 overexpression increased basal LC3-II levels, dependent on enzymatic activity,

More information

Classes of Neurotransmitters. Neurotransmitters

Classes of Neurotransmitters. Neurotransmitters 1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters

More information

Nicotine: Everything You Need to Know but Have Never Been Told

Nicotine: Everything You Need to Know but Have Never Been Told Bernd Mayer Pharmacology & Toxicology University of Graz, Austria Nicotine: Everything You Need to Know but Have Never Been Told Bernhard-Michael (Bernd) Mayer, PhD Professor & Chair Department of Pharmacology

More information

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease

More information

Immunotherapy for the Treatment of Parkinson's Disease

Immunotherapy for the Treatment of Parkinson's Disease University of Colorado, Boulder CU Scholar Undergraduate Honors Theses Honors Program Spring 2014 Immunotherapy for the Treatment of Parkinson's Disease Matthew Follett University of Colorado Boulder Follow

More information

Latest Research on the new Laser Watch

Latest Research on the new Laser Watch Latest Research on the new Laser Watch 1 Axel von Hirschheydt, MD Lauenfoerde/Germany 12th International Conference for Medical Laser Applications June 09/10 2017, Beverungen/Germany Research Network:

More information

IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY DOCTORAL SCHOOL NEUROSCIENCE SECTION 6 28 MARCH UMF IULIU HATIEGANU CLUJ-NAPOCA ROMANIA

IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY DOCTORAL SCHOOL NEUROSCIENCE SECTION 6 28 MARCH UMF IULIU HATIEGANU CLUJ-NAPOCA ROMANIA IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY DOCTORAL SCHOOL NEUROSCIENCE P R O G R A M 2016-2017 SECTION 6 28 MARCH UMF IULIU HATIEGANU CLUJ-NAPOCA ROMANIA 1 PhD NEUROSCIENCE PROGRAM COORDINATOR

More information

Neuropharmacology NOTES

Neuropharmacology NOTES Neuropharmacology NOTES Contents Topic Page # Lecture 1- Intro to Neurochemical Transmission & Neuromodulation 2 Lecture 2- Serotonin & Noradrenaline 7 Lecture 3- Acetylcholine & Dopamine 14 Lecture 4-

More information

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological

More information

DRUGS THAT ACT IN THE CNS

DRUGS THAT ACT IN THE CNS DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called

More information

CANNABIS AND NEUROLGICAL DISORDERS

CANNABIS AND NEUROLGICAL DISORDERS CANNABIS AND NEUROLGICAL DISORDERS Neurodegenerative diseases and movement disorders, which are sometimes interlinked, are among the many conditions that cannabis and cannabinoids may be particularly well

More information

Retrotope, Inc. A Clinical Stage Pharmaceutical Company

Retrotope, Inc. A Clinical Stage Pharmaceutical Company Reinforcing the molecules of life Retrotope, Inc. A Clinical Stage Pharmaceutical Company Retrotope has created a proprietary drug platform to preserve and restore cellular health in degenerative diseases.

More information

TIGAR's promiscuity Bolaños, Juan P.

TIGAR's promiscuity Bolaños, Juan P. TIGAR's promiscuity Bolaños, Juan P. TIGAR [TP53 (tumour protein 53)-induced glycolysis and apoptosis regulator] is an important survival factor for cancer cells. The enzymatic activity supported by sequence

More information

1. INTRODUCTION Parkinson's disease (PD)

1. INTRODUCTION Parkinson's disease (PD) 1. INTRODUCTION Parkinson's disease (PD) is a pathological condition that has been known for centuries through early Greek scientific descriptions, traditional Indian texts and ancient Chinese sources.

More information

11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley

11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley MICROBIOME AND THE BRAIN: How your gut impacts wellbeing Session One Sue Langley 2018 2017 Langley Group IP Trust Approach Lessons from Venice 1 Lessons from Venice Agenda 2. Implications and research

More information